Cytek Biosciences, Inc. provided revenue guidance for the fiscal year 2022. Cytek Biosciences expects full year 2022 revenue to be in the range of $160 million to $168 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.73 USD | +5.62% | -0.52% | -37.17% |
05-29 | Sector Update: Health Care Stocks Lean Lower Premarket Wednesday | MT |
05-29 | Cytek Biosciences Gets Approval for Clinical Use of TBNK Reagents in China | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-37.17% | 752M | |
+8.38% | 220B | |
+15.78% | 198B | |
+31.27% | 112B | |
+5.21% | 66.17B | |
+14.19% | 52.47B | |
+4.70% | 50.77B | |
-3.93% | 38.97B | |
-0.47% | 35.13B | |
+23.96% | 31.32B |
- Stock Market
- Equities
- CTKB Stock
- News Cytek Biosciences, Inc.
- Cytek Biosciences, Inc. Provides Revenue Guidance for the Fiscal Year 2022